Management of ATTR-CM After Switching from Tafamidis to Attruby
Continue Attruby (acoramidis) 712 mg orally twice daily as the primary disease-modifying therapy for this patient with progressive ATTR-CM. 1
Rationale for Attruby Continuation
Attruby (acoramidis) is FDA-approved specifically for treating ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization 1. The switch from tafamidis (Vyndamax) to Attruby is appropriate when disease progression occurs, as acoramidis represents a next-generation TTR stabilizer that achieves near-complete (≥90%) TTR stabilization—superior to older stabilizers 2.
Key advantages of acoramidis include:
- Higher degree of TTR stabilization compared to tafamidis
- Demonstrated reduction in cardiovascular mortality and hospitalization rates
- Improvement in quality of life measures
- Twice-daily oral dosing at 712 mg 1
Critical Monitoring Parameters
Since the patient experienced disease progression on tafamidis, aggressive monitoring is essential:
Cardiac biomarkers every 3 months:
- NT-proBNP levels (though heterogeneous response patterns exist) 3
- High-sensitivity cardiac troponin T 3
Functional assessments every 3-6 months:
Echocardiographic surveillance every 6 months:
- Global longitudinal strain (most sensitive for disease stabilization) 3
- Left ventricular wall thickness
- Ejection fraction (though reverse remodeling is uncommon) 3, 4
Important Clinical Considerations
Disease progression on tafamidis does not necessarily predict failure with acoramidis. The higher stabilization capacity of acoramidis may still provide clinical benefit even after tafamidis progression 2. However, realistic expectations are crucial—the goal is disease stabilization and slowing progression rather than reversal of cardiac damage 3.
Common pitfall: Expecting dramatic echocardiographic improvement. Studies show that while acoramidis stabilizes disease, marked reverse remodeling with improved ejection fraction or reduced chamber size is uncommon 3, 4. Stability of parameters represents therapeutic success.
Adjunctive Management
Heart failure optimization remains critical:
- Diuretics for volume management (primary symptomatic therapy)
- Avoid ACE inhibitors/ARBs due to poor tolerance in restrictive physiology
- Beta-blockers and calcium channel blockers often poorly tolerated
- Consider pyridostigmine for orthostatic hypotension if present (safer than fludrocortisone/midodrine in restrictive cardiomyopathy) 5
If concomitant neuropathy exists: Consider adding TTR silencer therapy (patisiran, vutrisiran, or inotersen) as these are specifically indicated for ATTRv polyneuropathy, though tafamidis/acoramidis are not FDA-approved for neuropathy 5, 6. This would require vitamin A supplementation 3,000 IU daily 5.
When to Reassess Treatment Strategy
Consider advanced therapies if:
- Progressive NYHA class deterioration despite 6 months of acoramidis
- Recurrent heart failure hospitalizations
- Rising biomarkers with clinical deterioration
- Development of refractory symptoms
At that point, evaluation for cardiac transplantation or mechanical circulatory support may be warranted, though these decisions require multidisciplinary amyloidosis team input.
The ECG findings should be monitored for: Progressive low voltage, pseudoinfarct patterns, or conduction abnormalities that may necessitate pacemaker or CRT consideration 4.